002755.SHE Beijing New Oriental Star Petrochemical Engineering Co Ltd
- Market cap
- CNY 11.1B
- P/E
- 62.8x
- P/B
- 3.30x
- ROE
- 6.9%
- Dividend yield
- 1.01%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002755.SHE undervalued?
Graham numberThe Graham number of Beijing New Oriental Star Petrochemical Engineering Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing New Oriental Star Petrochemical Engineering Co Ltd fundamental analysis
No fundamental analysis for Beijing New Oriental Star Petrochemical Engineering Co Ltd yet.
Beijing New Oriental Star Petrochemical Engineering Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing New Oriental Star Petrochemical Engineering Co Ltd
Beijing Aosaikang Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of active pharmaceutical ingredients and formulations in China. It also offers digestive health products, which include pump inhibitors suitable for various digestive tract-related diseases, such as peptic ulcers, reflux esophagitis, and upper gastrointestinal bleeding; and anti-tumor products, including the treatment of non-small cell lung cancer, colorectal cancer, and bre…
Full company profileBeijing New Oriental Star Petrochemical Engineering Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beijing New Oriental Star Petrochemical Engineering Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.09B | 3.40B | 3.93B | 4.52B | 3.78B | 3.11B | 1.87B | 1.44B | 1.78B | 1.78B | 1.66B |
| Gross Profit | 2.89B | 3.16B | 3.65B | 4.18B | 3.47B | 2.83B | 1.63B | 1.17B | 1.44B | 1.43B | 1.35B |
| Operating Income | 722M | 690M | 744M | 872M | 790M | 403M | -260M | -220M | 157M | 237M | 240M |
| EBITDA | 736M | 728M | 798M | 931M | 825M | 401M | -224M | -209M | 170M | 383M | 269M |
| Net Income | 630M | 608M | 670M | 781M | 722M | 380M | -226M | -149M | 160M | 237M | 226M |
| EPS | 4.02 | 0.80 | 0.89 | 0.84 | 0.78 | 0.41 | -0.24 | -0.16 | 0.17 | 0.25 | 0.24 |
| Balance Sheet | |||||||||||
| Total Assets | 691M | 867M | 2.96B | 3.69B | 3.81B | 3.72B | 3.41B | 3.52B | 4.05B | 4.52B | 4.38B |
| Total Liabilities | 181M | 282M | 1.12B | 1.18B | 775M | 497M | 401M | 513M | 905M | 1.24B | 1.03B |
| Shareholders' Equity | 509M | 519M | 1.84B | 2.51B | 3.03B | 3.22B | 2.96B | 2.90B | 3.06B | 3.22B | 3.28B |
| Cash & Short-term Investments | 271M | 190M | 1.08B | 1.29B | 1.47B | 1.69B | 1.61B | 1.76B | 2.09B | 1.42B | 1.23B |
| Total Debt | 3.00M | 10.9M | 4.09M | 554K | 20.0M | 14.1M | 57.4M | 121M | 68.6M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 16.7M | -50.3M | 497M | 535M | 580M | 568M | -52.8M | -26.6M | 411M | 652M | - |
| Capital Expenditure | 4.10M | 3.87M | 95.8M | 169M | 200M | 134M | 150M | 129M | 230M | 144M | 280M |
| Free Cash Flow | 12.6M | -54.2M | 401M | 366M | 381M | 434M | -203M | -156M | 181M | 508M | 45.8M |
| Ratios | |||||||||||
| ROE | 123.7% | 117.0% | 36.5% | 31.1% | 23.8% | 11.8% | -7.6% | -5.1% | 5.2% | 7.4% | 6.9% |
| ROA | 91.2% | 70.1% | 22.7% | 21.2% | 18.9% | 10.2% | -6.6% | -4.2% | 4.0% | 5.2% | 5.2% |
| Net Profit Margin | 20.4% | 17.8% | 17.0% | 17.3% | 19.1% | 12.2% | -12.1% | -10.3% | 9.0% | 13.3% | 13.6% |
| Debt to Equity | 0.01x | 0.02x | 0.00x | 0.00x | 0.01x | 0.00x | 0.02x | 0.04x | 0.02x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beijing New Oriental Star Petrochemical Engineering Co Ltd dividends
- Dividend yield
- 1.01%
- Forward dividend
- 0.12 CNY
- Payout ratio
- 47.1%
- Ex-dividend date
- Jun 18, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 111M | 0.12 | 47.1% |
| 2024 | CNY 1.16M | 0.00 | 0.7% |
| 2023 | CNY 1.12M | 0.00 | - |
| 2022 | CNY 92.8M | 0.10 | - |
| 2021 | CNY 186M | 0.20 | 48.9% |
| 2020 | CNY 204M | 0.22 | 28.3% |
| 2019 | CNY 111M | 0.12 | 14.3% |
| 2018 | CNY 488K | 0.00 | 0.1% |
| 2017 | CNY 1.22M | 0.00 | 0.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.7:1 on May 31, 2018.
Who owns Beijing New Oriental Star Petrochemical Engineering Co Ltd
- Insiders 71.23%
- Institutions 6.92%
- Public & others 21.85%
- Shares outstanding 928M
- Free float 267M
Beijing New Oriental Star Petrochemical Engineering Co Ltd company profile
- Company name
- Beijing New Oriental Star Petrochemical Engineering Co Ltd
- Ticker
- 002755.SHE
- ISIN
- CNE100001X92
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 799
- Fiscal year end
- December
- Address
- Jiangning Science Park, Nanjing, China, 211112
- Phone
- 86 25 5216 9999
- Website
- ask-pharm.com
About Beijing New Oriental Star Petrochemical Engineering Co Ltd
Beijing Aosaikang Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of active pharmaceutical ingredients and formulations in China. It also offers digestive health products, which include pump inhibitors suitable for various digestive tract-related diseases, such as peptic ulcers, reflux esophagitis, and upper gastrointestinal bleeding; and anti-tumor products, including the treatment of non-small cell lung cancer, colorectal cancer, and breast cancer, encompassing targeted therapy, chemotherapy, endocrine therapy, and adjuvant medications. In addition, the company provides anti-infective products comprising a product defense line against bacterial and invasive fungal infections; and the chronic disease field focusing on chronic diseases requiring long-term management consisting of diabetes, osteoarthritis, thrombocytopenia, and iron overload. Beijing Aosaikang Pharmaceutical Co., Ltd. was founded in 1996 and is based in Nanjing, China.
Beijing New Oriental Star Petrochemical Engineering Co Ltd management
3- Mr. Jingfei MaGM & Director · born 1988
- Mr. Tao HanCFO & Head of Accounting Department · born 1982
- Mr. Xiangfeng ChenDeputy GM & Non-Independent Director · born 1970